Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02267135 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Phase 3 study of Chronic Scalp Psoriasis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 102
- Enrollment target
- 17
- Study locations
NCT02267135: Completed Phase 3 study of Chronic Scalp Psoriasis, sponsored by Novartis Pharmaceuticals.
NCT02267135 is a Phase 3 study of Chronic Scalp Psoriasis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 102 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). The trial reports 17 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02267135, a Phase 3 study of Chronic Scalp Psoriasis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 102 participants
- Enrollment target
- 17
- Study locations
Study Summary
This study will assess the efficacy and safety of secukinumab compared to placebo in adult patients who have moderate to severe scalp psoriasis that is poorly controlled by current psoriasis treatments.
Primary Outcome
PSSI 90 response (yes) at Week 12; PSSI 90 response means at least a 90% improvement in scalp psoriasis Percentage of participants with Psoriasis Scalp Severity Index 90 (PSSI 90) response of "yes"
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Secukinumab 300 mg
Study Locations (17)
Massachusetts
- Novartis Investigative Site - Andover
- Novartis Investigative Site - Boston
New York
- Novartis Investigative Site - New York
- Novartis Investigative Site - New York
Pennsylvania
- Novartis Investigative Site - Hershey
- Novartis Investigative Site - Pittsburgh
Utah
- Novartis Investigative Site - Salt Lake City
- Novartis Investigative Site - West Jordan
California
- Novartis Investigative Site - Sacramento
Colorado
- Novartis Investigative Site - Aurora
Connecticut
- Novartis Investigative Site - Trumbull
Maryland
- Novartis Investigative Site - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2014-09-29 |
| Est. Completion | 2015-12-07 |
| Phase | Phase 3 |
What the finished NCT02267135 record still lists
NCT02267135 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Chronic Scalp Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02267135 lists 17 locations in 13 states (Massachusetts, New York, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT02267135 about?
NCT02267135 is a clinical study titled "Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis". This study will assess the efficacy and safety of secukinumab compared to placebo in adult patients who have moderate to severe scalp psoriasis that is poorly controlled by current psoriasis treatments.
What is the current status of trial NCT02267135?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 102 participants. The study started on 2014-09-29. Estimated completion is 2015-12-07.
What conditions does trial NCT02267135 study?
This clinical trial studies the following conditions: Chronic Scalp Psoriasis.
What interventions are being tested in trial NCT02267135?
The interventions under investigation include: Placebo (BIOLOGICAL), Secukinumab 300 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT02267135?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02267135 being conducted?
This trial has 17 study locations across California, Colorado, Connecticut, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02267135's enrollment target sits among peer trials
102 1676th of 2000 higher than 321 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI